(+)-Norfenfluramine-induced arterial contraction is not dependent on endogenous 5-hydroxytryptamine or 5-hydroxytryptamine transporter

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 3, 2005, Pages 953-960

  Ni, Wei ^a   Wilhelm, Claudia S ^b   Bader, Michael ^b   Murphy, Dennis L ^c   Lookingland, Keith ^a   Watts, Stephanie W ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; FLUVOXAMINE; KETANSERIN; NORFENFLURAMINE; PARGYLINE; SEROTONIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE;

ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; MALE; MOUSE; MUSCLE ISOMETRIC CONTRACTION; MUTATION; NONHUMAN; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE; WILD TYPE;

ANIMALS; AORTA; FLUOXETINE; FLUVOXAMINE; KETANSERIN; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; NORFENFLURAMINE; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TRYPTOPHAN HYDROXYLASE; VASOCONSTRICTION;

EID: 23944495391     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.087080     Document Type: Article

References (26)

1. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, et al. (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 355:609-616.
2. Barnes NM and Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-1152.
3. Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heils A, Mossner R, Westphal H, and Lesch KP (1998) Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol Pharmacol 53:649-655.
4. Chang AS, Chang SM, Starnes DM, Schroeter S, Bauman AL, and Blakely RD (1996) Cloning and expression of the mouse serotonin transporter. Brain Res Mol Brain Res 43:185-192.
5. Chapin DS, Lookingland KJ, and Moore KE (1986) Effects of LC mobile phase composition on retention times for biogenic amines and their precursors and metabolites. Curr Sep 7:68-70.
6. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, and Schaff HV (1997) Valvular heart disease associated with fenfluraminephentermine. N Engl J Med 337:581-588.
7. Fishman AP (1999) Aminorex to fen/phen: an epidemic foretold. Circulation 99:156-161.
8. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, et al. (2000) Possible role of valvular serotonin 5-HT 2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75-81.
9. Garattini S (1995) Biological actions of drugs affecting serotonin and eating. Obes Res 3 (Suppl 4):463S-470S.
10. Holmes A, Yang RJ, Murphy DL, and Crawley JN (2002) Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology 27:914-923.
11. Hong Z, Olschewski A, Reeve HL, Nelson DP, Hong F, and Weir EK (2004) Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol 286:L531-L538.
12. Johnson GJ, Leis LA, Dunlop PC, and Weir EK (2003) The effect of the anorectic agent, d-fenfluramine and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux. J Thromb Haemost 1:2663-2668.
13. Korstanje C, Sprenkels R, Doods HN, Hugtenburg JG, Boddeke E, Batink HD, Thoolen MJ, and Van Zwieten PA (1986) Characterization of flufylline, fluprofylline, ritanserin, butanserin and R 56413 with respect to in-vivo alpha 1-,alpha 2-and 5-HT 2-receptor antagonism and in-vitro affinity for alpha 1-,alpha 2- and 5-HT 2-receptors: comparison with ketanserin. J Pharm Pharmacol 38:374-379.
14. 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol 21:301-314.
15. Mabadeje AF (1974) Proceedings: fenfluramine-induced hypertension. West Afr J Pharmacol Drug Res 2:54.
16. Martin GR (1994) Vascular receptors for 5-hydroxytryptamine: distribution, function and classification. Pharmacol Ther 62:283-324.
17. McKune CM and Watts SW (2001) Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling. J Pharmacol Exp Ther 297:88-95.
18. Ni W, Li MW, Thakali K, Fink GD, and Watts SW (2004a) The fenfluramine metabolite (+)-norfenfluramine is vasoactive. J Pharmacol Exp Ther 309:845-852.
19. Ni W, Thompson JM, Northcott CA, Lookingland K, and Watts SW (2004b) The serotonin transporter is present and functional in peripheral arterial smooth muscle. J Cardiovasc Pharmacol 43:770-781.
20. Rezaie-Majd S, Murar J, Nelson DP, Kelly RF, Hong Z, Lang IM, Varghese A, and Weir EK (2004) Increased release of serotonin from rat ileum due to dexfenfluramine. Am J Physiol 287:R1209-R1213.
21. Rothman RB and Baumann MH (2002) Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 95:73-88.
22. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, and Roth BL (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836-2841.
23. Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, Birkes J, Young R, and Glennon RA (2003) (+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters. J Pharmacol Exp Ther 305:1191-1199.
24. Russell A and Watts SW (2000) Vascular reactivity of isolated thoracic aorta of the C57BL/6J mouse. J Pharmacol Exp Ther 294:598-604.
25. Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H, and Bader M (2003a) Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science (Wash DC) 299:76.
26. Walther DJ, Peter JU, Winter S, Holtje M, Paulmann N, Grohmann M, Vowinckel J, Alamo-Bethencourt V, Wilhelm CS, Ahnert-Hilger G, et al. (2003b) Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alphagranule release. Cell 115:851-862.